Consolidated figures · ₹ crore
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 3,609 | 4,162 | 5,973 | 5,427 | 6,601 | 6,642 | 7,922 | 9,039 | 9,827 | |
| COGS | 1,621 | 1,963 | 2,328 | 1,499 | 1,921 | 1,582 | 2,149 | 2,408 | 2,662 |
| Gross profit | 1,989 | 2,199 | 3,644 | 3,928 | 4,680 | 5,059 | 5,773 | 6,631 | 7,165 |
| 1,752 | 1,876 | 3,253 | 3,660 | 4,404 | 4,752 | 5,354 | 6,074 | 6,469 | |
| 236 | 324 | 392 | 269 | 276 | 307 | 419 | 557 | 696 | |
| OPM % | 6.6% | 7.8% | 6.6% | 5% | 4.2% | 4.6% | 5.3% | 6.2% | 7.1% |
| Depreciation | 72 | 73 | 83 | 80 | 80 | 94 | 101 | 115 | 155 |
| Interest | 127 | 125 | 143 | 83 | 70 | 100 | 121 | 164 | 167 |
| 8 | 23 | 9 | 38 | 253 | 52 | 26 | 15 | 4 | |
| Profit before tax | 45 | 148 | 174 | 143 | 379 | 165 | 223 | 292 | 377 |
| Tax | — | — | 59 | 11 | 39 | 24 | 50 | 61 | 84 |
| Tax % | — | — | 34.1% | 7.9% | 10.4% | 14.5% | 22.5% | 21% | 22.4% |
| 35 | 97 | 115 | 132 | 340 | 141 | 173 | 231 | 293 | |
| PAT margin % | 1% | 2.3% | 1.9% | 2.4% | 5.2% | 2.1% | 2.2% | 2.6% | 3% |
| EPS (₹) | — | — | 37 | 42.5 | 109.8 | 45.6 | 55.9 | 74.6 | 46 |
| EPS adjusted (₹) | 5.7 | 15.6 | 18.5 | 21.3 | 54.9 | 20.2 | 27.9 | 37.3 | 43.7 |
| — | — | 16.2% | 14.1% | 6.8% | 16.5% | 14.3% | 6.7% | — | |
| Annual report | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 34 |
| Reserves | 721 | 814 | 932 | — | 1,138 | 1,761 | 1,870 | 2,020 | 2,225 | 2,899 |
| 945 | 751 | 863 | — | 1,123 | 1,040 | 1,094 | 1,321 | 1,804 | 1,578 | |
| 1,795 | 1,825 | 1,959 | — | 1,828 | 1,799 | 1,863 | 2,245 | 2,116 | 2,012 | |
| Total equity & liabilities | 3,492 | 3,421 | 3,784 | — | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,523 |
| 2,110 | 2,155 | 2,165 | 2,220 | 2,185 | 2,310 | 2,709 | 3,198 | 3,827 | 4,553 | |
| CWIP | 91 | 89 | 137 | — | 126 | 243 | 125 | 84 | 98 | 37 |
| Investments | 25 | 24 | 21 | — | 35 | 344 | 326 | 342 | 383 | 391 |
| 1,266 | 1,153 | 1,461 | — | 1,774 | 1,734 | 1,698 | 1,993 | 1,867 | 1,543 | |
| Total assets | 3,492 | 3,421 | 3,784 | — | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,523 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Potable Spirits | 6,946.43 | 284.93 | 596.6 | 326.53 | 270.07 | 105.5 |
| Bio-Fuel | 1,469.93 | 115.23 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 302 | 502 | 147 | 293 | 81 | 91 | 326 | 439 | 362 | 769 | |
| -40 | -103 | -128 | -147 | -131 | 93 | -330 | -503 | -736 | -767 | |
| -263 | -399 | 3 | -169 | 49 | -181 | -1 | 90 | 354 | 23 | |
| Net cash flow | — | -0 | 22 | — | -0 | 4 | -5 | 25 | -20 | 25 |
| Free cash flow | 260 | 372 | 8 | — | -68 | -289 | -113 | -114 | -398 | -54 |
| CFO / Operating profit % | 127.8% | 155.1% | — | 74.7% | 30.3% | 35.8% | 110.2% | 109% | 70.9% | 118.5% |
| 1,429.96 |
| 92.27 |
| 1,337.69 |
| 8.61 |
| Bio-based Specialities and Performance Chemicals | 1,202.5 | 140.95 | 3,600.59 | 737.97 | 2,862.62 | 4.92 |
| Ennature Biopharma | 207.77 | 7.23 | 426.42 | 92.49 | 333.93 | 2.17 |
₹ crore by fiscal year